«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:

33

期数:

2016年6

页码:

500-503

栏目:

临床研究

出版日期:

2016-06-05

文章信息/Info

Title:

Effect of Xiaoaiping injection combined with CapeOX regimen for patients with advanced colorectal cancer

作者:

寇卫政¹; 杨晓煜²; 褚秀峰¹; 苗战会¹; 路　平¹

（1.新乡医学院第一附属医院肿瘤科，河南　卫辉　453100；2.新乡医学院第一附属医院病理科，河南　卫辉　453100）

Author(s):

KOU Wei-zheng¹; YANG Xiao-yu²; CHU Xiu-feng¹; MIAO Zhan-hui¹; LU Ping¹

（1.Department of Oncology，the First Affiliated Hospital of Xinxiang Medical University，Weihui 453100，Henan Province，China；2.Department of Pathology，the First Affiliated Hospital of Xinxiang Medical University，Weihui 453100，Henan Province，China）

关键词:

晚期结直肠癌; CapeOX方案; 消癌平注射液

Keywords:

advanced colorectal cancer; CapeOX regimen; Xiaoaiping injection

分类号:

R735.3

DOI:

10.7683/xxyxyxb.2016.06.015

文献标志码:

A

摘要:

目的　评价消癌平注射液联合CapeOX方案对晚期结直肠癌的疗效、不良反应及免疫功能的影响。方法　73例晚期结直肠癌患者随机分为2组，观察组37例接受消癌平注射液联合CapeOX方案治疗，对照组36例接受CapeOX方案治疗，治疗2个周期后比较2组患者的近期疗效，生活质量，不良反应情况，血清肿瘤标志物癌胚抗原（CEA），糖蛋白抗原（CA-199），及CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺变化。结果　完成2个周期化学治疗后，观察组患者的客观缓解率、疾病控制率、生活质量总改善率均显著高于对照组（P<0.05）。2组患者均无因严重不良反应而停药者，各种不良反应发生率比较差异无统计学意义（P>0.05）。2组患者治疗前血清CEA、CA-199水平比较差异均无统计学意义（P>0.05）；观察组和对照组患者治疗后血清CEA、CA-199水平均低于治疗前（P<0.05）；治疗后观察组患者血清CEA、CA-199水平均低于对照组（P<0.05）。观察组和对照组患者治疗前血清CD3⁺、CD4⁺、CD8⁺水平及CD4⁺/CD8⁺比较差异均无统计学意义（P>0.05）；2组患者治疗后血清CD3⁺、CD4⁺水平及CD4⁺/CD8⁺与治疗前比较差异均无统计学意义（P>0.05）；治疗后观察组患者血清CD3⁺、CD4⁺水平及CD4⁺/CD8⁺均较对照组升高（P<0.05）；2组患者治疗后血清CD8⁺水平比较差异无统计学意义（P>0.05）。结论　消癌平注射液联合CapeOX方案治疗晚期结直肠癌患者可提高客观缓解率、疾病控制率及生活质量，改善机体免疫功能，值得临床进一步应用。

Abstract:

Objective　To evaluate the therapeutic effect，adverse reaction and immune function of Xiaoaiping injection combined with CapeOX regimen for patients with advanced colorectal cancer.Methods　A total of 73 patients with advanced colorectal cancer were randomly divided into two groups，37 cases in observation group were given Xiaoaiping injection combined with CapeOX regimen，and 36 cases in control group were given CapeOX regimen.The short-term efficacy，quality of life，adverse reactions and the changes of serum tumor markers carcinoembryonic antigen（CEA），carbohydrate antigen 199（CA-199），CD3⁺，CD4⁺，CD8⁺，CD4⁺/CD8⁺in the two groups were compared after two cycles of treatment.Results　After completing two cycles of chemotherapy of patients in the two groups，the objective response rate（ORR） of patients and disease contral rate（DCR） in the observation group were significantly higher than those in the control group （P<0.05）.The total improvement rate of quality of life of patients in the observation group was significantly higher than that in the control group （P<0.05）.There is no discontinuation in the two groups of patients due to serious adverse reaction，and the adverse reaction rate had no significant difference （P>0.05）.There was no significant difference in the serum tumor markers CEA，CA-199 level between the observation group and the control group before treatment （P>0.05）.The serum tumor markers CEA，CA-199 levels after treatment were lower than those before treatment in observation group and control group （P<0.05）.After treatment，the serum tumor markers CEA，CA-199 levels of patients in the observation group were lower than those in the control group，the difference was statistically significant （P<0.05）.The serum CD3⁺，CD4⁺，CD8⁺，CD4⁺/CD8⁺levels were not statistically significant difference between the observation group and control group patients before treatment （P>0.05）.Compared with before treatment，there was no significant difference in the serum CD3⁺，CD4⁺，CD8⁺，CD4⁺/CD8⁺levels after treatment in the control group and observation group （P>0.05）.After treatment，the serum CD3⁺，CD4⁺，CD4⁺/CD8⁺levels of patients in the observation group were higher than those in control group （P<0.05）.There was no significant difference in serum CD8⁺level between the two groups after treatment （P>0.05）.Conclusion　Xiaoaiping injection combined with CapeOX regimen of treatment in advanced colorectal cancer can improve the ORR，DCR，quality of life and immune function，suggesting its potential value for further clinical applications.

常用功能

更新日期/Last Update: 2016-06-05